OraSure Technologies (NASDAQ:OSUR) Issues Earnings Results

OraSure Technologies (NASDAQ:OSUR) posted its earnings results on Tuesday. The medical instruments supplier reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05), Zacks reports. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%.

OraSure Technologies Stock Up 0.3 %

Shares of OSUR stock traded up $0.01 during mid-day trading on Tuesday, reaching $4.00. 768,623 shares of the company’s stock traded hands, compared to its average volume of 810,206. The company’s 50-day moving average price is $3.80 and its 200-day moving average price is $4.02. The company has a market cap of $298.38 million, a P/E ratio of 26.67 and a beta of 0.05. OraSure Technologies has a 12 month low of $3.52 and a 12 month high of $8.04.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.